Kevin Gorman: Yes. The dynamics with regards to telemedicine, I think, have been relatively stable over the past year or two, and there is a pretty significant difference between psychiatry and really all other specialties within our health care system. Early in the pandemic, we saw this significant jump in the use of telemedicine across both the neurology and the psychiatry segments. But as the environment improved and restrictions were lessened, patients started to come back into the clinics and so on. We saw that neurology went back towards its more historical levels of less than 10% of visits being billed as telemedicine visit. In psychiatry, however, or in behavioral health, that’s significantly higher. It’s still hovering around half of all visits being billed as telemedicine visits.
And so we think that is here to stay, that it has some staying power in psychiatry, even though COVID has diminished quite a bit. And the other dynamic, I think, that’s important to note in psychiatry is really the – expanded use of advanced practice providers in that segment. And so those two macro factors, I think, are important to understand what’s happening in psychiatry in general in our psychiatry business, in particular, telemedicine, which creates a little bit of challenge for some providers with diagnosing TD though, I think that we’ve adapted nicely to it in terms of helping providers understand how to screen for how to diagnose TD remotely when they’re evaluating a patient via telemedicine. And then the important work that we’re doing to educate new providers coming into psychiatry, nurse practitioners, physician associates and so on.
And so we continue to evolve as the market evolves, but the important thing is that the majority of patients still are undiagnosed, and we’re continuing to invest in driving diagnosis and treatment. The other element that I’ll throw in there, like Matt just mentioned the importance of bringing in another factor. We continue to invest in DTC and DTC is one mechanism that we have to reach patients and care partners directly to motivate them to bring up their TD symptoms and to drive diagnosis. And so all of these things, I think, are important as you think about future growth for the franchise. But the ceilings high and we’re continuing to see strong growth, and I think that our raised guidance reflects that.
Operator: We will take our next question from Uy Ear with Mizuho. Your line is open.
Uy Ear: Hi, guys. Thanks for taking my question. I might have missed it, but could you tell us what the volume growth rate is for INGREZZA in the quarter? And could you also speak to the – provide some more color on the neuros, the neurology, the psychiatry and the long-term care in terms of contributions to this quarter’s sales and growth rates? Thanks.
Matt Abernethy: So when you think about volume growth, it was incredibly strong from a dollar perspective, you had about a 20% – 26% year-over-year growth, which was quite nice. And as I said earlier, we did have the bleed of inventory that’s also reflected in the number that we’ve reported. So we haven’t provided the exact volume growth percentage, but it was quite strong during the quarter.
Operator: We have addressed all the questions in the queue. I would now like to turn the program back over to Kevin for any additional or closing remarks.
Kevin Gorman: Thank you very much, and thank you for all your questions this morning. I’m just going to close with the fact that we’ve – some of you may become a bit too used to INGREZZA, just growing quarter after quarter. And while we see this growth continuing, we never take it for granted. This is a tremendous amount of hard work that goes in from our entire sales, marketing team, the medical team and all the other support teams that are out there in the field. We’re able to continue to bring this medicine to more and more patients suffering with TD because of those hard efforts. And yet we see no slowdown in this. That is just incredible. And we are a very fortunate company to have a product like this. They do not come along very often.
